NCT03689829 - A Study to Test Safety, Tolerability, and the Way the Body Absorbs, Distributes, and Gets Rid of a Study Drug Called MOR106, in Healthy Subjects and in Patients With Moderate to Severe Atopic Dermatitis | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

August 13, 2018

Primary Completion Date

March 2, 2020

Study Completion Date

March 2, 2020

Conditions

HealthyAtopic Dermatitis

Interventions

DRUG

MOR106

The active pharmaceutical drug substance of MOR106 is a human immunoglobulin gamma-1 (IgG1) monoclonal antibody that binds with a high apparent affinity to human interleukin-17C (IL-17C).

DRUG

Placebo

Corresponding placebo s.c. injections.

Trial Locations (15)

1307

University Hospital Carl Gustav Carus, Dresden

28034

Hospital Ramon y Cajal, Madrid

39120

Medical Faculty University Clinic Magdeburg, University dermatology clinic, Magdeburg

41009

Hospital Universitario Virgen Macarena, Seville

45657

Vest Clinic, Department of Dermatology and Allergy, Recklinghausen

46014

Hospital General Universitario de Valencia, Valencia

86179

Klinikum Augsburg Süd, Augsburg

91054

University Hospital Erlangen, Department of Dermatology, Erlangen

06847

Municipal Hospital Dessau, Dessau

03010

Hospital General Universitario de Alicante, Alicante

08112

Arensia, Kapitanivka

Unknown

MEU, Manchester

HA6 2RN

MeDiNova North London, Northwood

RM1 3PJ

MeDiNova East London, Romford

DA14 6LT

MeDiNova South London, Sidcup